Ad
related to: methylxanthines for apnea medication information release side effects
Search results
Results from the WOW.Com Content Network
Theophylline extended-release tablets in Japan. Theophylline, also known as 1,3-dimethylxanthine, is a drug that inhibits phosphodiesterase and blocks adenosine receptors. [1] It is used to treat chronic obstructive pulmonary disease (COPD) and asthma. [2] Its pharmacology is similar to other methylxanthine drugs (e.g., theobromine and caffeine ...
Inhaled short-acting β2-adrenergic agonists, such as terbutaline and salbutamol, are the first-line drugs indicated for asthma exacerbation for all patients to provide rapid bronchodilating effects. [ 1 ] [ 2 ] Short-acting β2-adrenergic agonists can be delivered by different devices, for example, nebulizers and metered-dose inhalers .
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. ... Zepbound's side effects can include nausea, diarrhea, vomiting ...
It is a combination drug containing three active ingredients - theophylline, ephedrine, phenobarbital. [2] This medication relaxes the smooth muscle of the airways, making breathing easier. [3] The common side effects of Tedral include gastrointestinal disturbances, dizziness, headache and lightheadedness.
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. The approval opens up a wide market of patients for Lilly at a time when ...
7-Methylxanthine (7-MX), also known as heteroxanthine, is an active metabolite of caffeine (1,3,7-trimethylxanthine) and theobromine (3,7-dimethylxanthine). [ 1 ] [ 2 ] It is a non-selective antagonist of the adenosine receptors .
Lilly evaluated its GLP-1 drug called tirzepatide, sold as Zepbound for obesity and Mounjaro for type 2 diabetes, in patients with obstructive sleep apnea and obesity.
Ad
related to: methylxanthines for apnea medication information release side effects